美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

KaloBios Pharmaceuticals Inc.

2.95

0.0000

成交量：2.05萬

成交額：6.05萬

市值：- -

市盈率：- -

高：1.66

開：1.63

低：1.60

收：2.95

52周最高：1.66

52周最低：1.60

股本：- -

流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

KaloBios Pharmaceuticals Inc.

交易所：

- -

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.kalobios.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

<p>美國生物製藥公司KaloBios提交IPO申請，計劃籌集6000萬美元，擬在納斯達克上市，代碼KBIO，Leerink Swann 是此次交易的唯一承銷商。KBIO創立於2001年，截至2012年6月30日的12個月錄得1800萬美元的銷售額。目前發行價格區間暫未披露。</p>

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/KBIO/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"KBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KBIO\",,,,,undefined,":{"symbol":"KBIO","market":"US","secType":"STK","nameCN":"KaloBios Pharmaceuticals Inc.","latestPrice":2.95,"timestamp":1501272000000,"preClose":2.95,"halted":0,"volume":20500,"delay":0,"changeRate":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":0,"latestTime":"07-28 16:00:00 EDT","open":1.63,"high":1.66,"low":1.6,"amount":60475.00000000001,"amplitude":0.020339,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":5,"adr":0,"listingDate":1359608400000,"adjPreClose":2.95,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KBIO\",,,,,undefined,":{"symbol":"KBIO","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":1.66,"amplitude":0.020339,"preClose":2.95,"low":1.6,"week52Low":1.6,"pbRate":"--","week52High":1.66,"institutionHeld":0,"latestPrice":2.95,"eps":0,"divideRate":0,"volume":20500,"delay":0,"open":1.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-09-05","symbol":"KBIO","name":"KaloBios Pharmaceuticals Inc.","time":"","type":"earning","dateTimestamp":1473048000000,"reportTimeType":""}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KBIO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.kalobios.com","compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0615},{"period":"3month","weight":-0.0655},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1345},{"period":"ytd","weight":-0.054}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"<p>美國生物製藥公司KaloBios提交IPO申請，計劃籌集6000萬美元，擬在納斯達克上市，代碼KBIO，Leerink Swann 是此次交易的唯一承銷商。KBIO創立於2001年，截至2012年6月30日的12個月錄得1800萬美元的銷售額。目前發行價格區間暫未披露。</p>","name":"KaloBios Pharmaceuticals Inc.","nameEN":"KaloBios Pharmaceuticals, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"KBIO\",market:\"US\",,,undefined,":null}}